**Supplementary Text**

**Patients:** This serological antibody survey was performed with serum samples from 42 non‑randomised volunteers collected on April 9, 2020. Individuals were from the same local area with direct or indirect contact to a German index patient with a PCR confirmed SARS‑CoV-2 infection on February 24, 2020. All individuals answered a questionnaire which was asking for a statement whether PCR testing for SARS-CoV-2 had been already performed. In addition, symptoms and their onset were queried, if applicable. Due to the small cohort size a classification of the severity of symptoms in PCR confirmed cases was not performed.

**Ethical statement:** The study was approved by the local ethics committee (study number: 5350). Written informed consent was given from each included individual.

**Commercially available Anti-SARS-CoV-2 tests systems:** All samples were tested for Anti‑SARS-CoV-2 antibodies with commercially available test systems from four manufacturers EUROIMMUN (EI), Roche, Abbott and DiaSorin recognising either antibodies directed against the SARS-CoV-2 virus spike (S) protein or against the nucleocapsid (N). The Euroimmun ELISA directed against the S1 domain of the spike protein detecting type IgA and IgG was performed on the Euroimmune Analyzer I-2P according to manufacturer's instructions. An OD ratio ≥1.1 for IgA and IgG was considered positive, ≤0.8 as negative and ≥0.8 ≤1.1 as borderline. Upper detection limits were OD ratio=7 for IgA and OD ratio =10 for IgG. IgG antibodies against the S1/S2 domains of SARS-CoV-2 spike were detected through a chemiluminescent immunoassay (CLIA) from DiaSorin on a LIAISONX. SARS-CoV-2 S1/S2 IgG antibody concentrations are calculated automatically and given as arbitrary units (AU/mL). Samples <12 AU/ml were interpreted as negative, 12-15 AU/ml as borderline and ≥ 15 AU/ml as positive. The Elecsys® Anti-SARS-CoV-2 electrochemiluminescence immunoassay (ECLIA) from Roche was performed on a cobas e801 immunoassay analyser for the detection of antibodies (including IgG) against the N antigen of SARS-CoV-2. The cut-off was automatically calculated based on the measurement of two calculators and the result was given as the signal sample to cutoff (COI) COI <1.0 is non-reactive or negative for Anti-SARS-CoV‑2 antibodies and COI ≥1.0 is considered positive. The SARS‑CoV‑2 IgG chemiluminescent microparticle immunoassay (CMIA) from Abbott detects IgG antibodies to N. The relation of chemiluminescent RLU in the reaction and the calibrator is given as the calculated index (S/C). An index (S/C) ≥1.4 is considered positive and <1.4 as negative. Measurements were performed on an ARCHITECT i2000 SR.

**Cell culture:** Vero cells (ATCC-CCL-81 obtained LGC Standards) were grown in Dulbecco’s modified essential medium (DMEM) supplemented with 1% penicillin and streptomycin (Gibco, 100 U/mL Penicillin and 100 µg/mL Streptomycin) and 2% fetal calf serum (FCS, PAN Biotech) and were cultured in a 5% CO2 humified atmosphere at 37 °C. Twice a week cells were sub-cultured at a ratio of 1:5 to 1:10.

**SARS-CoV-2 virus isolate:** For the neutralisation assay, SARS-CoV-2 isolate NRW-42 was used (EPI\_ISL\_425126). Sequencing showed 8 nucleotide exchanges in comparison to the reference virus Wuhan-Hu-1 [1].

**Neutralisation assay (NT):** To detect the presence and abundance of specific antibodies to SARS‑CoV-2, a neutralisation assay was performed modified, according to Gauger and Vincent [2]. Patient sera were heat inactivated for 30 min at 56 °C and briefly centrifuged. In 96-well flat bottom tissue plates, initial 1:5 dilutions of the sera were prepared in duplicate per patient for subsequent two-fold serial dilutions which were performed in 50µl volume with DMEM (1% penicillin and streptomycin, 2% FCS). An equal volume of a 1:50 dilution of the virus stock prepared with the same medium was added to the sera dilutions as well as to control sera and virus only controls where no serum was present. Cell-free plates were then pre-incubated at 37 °C, 5% CO2 for 1 h. After pre-incubation, 100µl of cell suspension containing 7×104/ml Vero cells in DMEM (1% penicillin and streptomycin, 2% FCS) were added to each well and to cell growth control wells were no serum or virus was present. Plates were incubated at 37 °C, 5% CO2 for 4 days. By microscopic inspection of the plates, the titre of neutralising antibodies was determined by the highest serum dilution with a 50 % reduction of cytopathic effect (CPE) compared to the virus control. The reciprocal of the serum dilution is given as the NT titre. The lowest serum dilution tested was 1:10 and a neutralisation titre of ≥20 was considered positive. Eleven sera sampled before December 2019 from healthy controls and two samples with documented coronavirus HCoV-229E and HCoV-NL63 infections served as negative controls.

**Immunofluorescence test (IFT):**  Vero cells (ATCC-CCL-81) were seeded at a density of 104 cells per well into a 48-well plate. After 24 hours, cells were infected with SARS-CoV-2 NRW-42 isolate (TCID50 of 50). Control cells were not infected. At day two p.i., fixation was performed with ice-cold methanol for 20 minutes at ‑20°C. Subsequently, cells were washed three times with PBS and permeabilised with 0.5 % Triton X-100 in PBS for 20 minutes. Cells were washed again three times. Patient sera were diluted 1 to 40 in PBS containing 5 % fetal calf serum (PAN Biotech, Germany). Vero cells were incubated in 200 µL diluted patient serum per well, for 2 hours at room temperature. Two wells containingSARS-CoV-2 infected and one well with uninfected cells were treated per patient. Positive control serum was obtained from a patient with high levels of Anti-SARS‑CoV-2 IgG (IgG OD ratio of 10 in EUROIMMUN ELISA). After a next washing step, cells were incubated for 1 hour at room temperature with Anti-human IgG FITC conjugate (Life technologies, USA,) diluted 1 to 40 in PBS containing 0.1 % Evansblue and 5 % fetal calf serum. Cells were washed three times with PBS and analysed via microscopy. Samples were categorised as positive or negative by two independent individuals.

**Statistical Analysis:** GraphPad Prism version 8.0.2 was used for statistical analysis. Pearson correlation analysis was used to assess correlation between serological assays. Good correlation was assumed if r≥0.5 and moderate if r≥0.3 in combination with p≤0.05. One-way analysis of variance (ANOVA) was performed for comparison between groups after checking for normal distribution. The respective p-values are given\*\*p≤0.01 \*\*\*p≤0.001.

References

1. Walker A, Houwaart T, Wienemann T, Vasconcelos MK, Strelow D, Senff T, et al. Genetic structure of SARS-CoV-2 reflects clonal superspreading and multiple independent introduction events, North-Rhine Westphalia, Germany, February and March 2020. Eurosurveillance. 2020;25(22):2000746.

2. Gauger PC, Vincent AL. Serum virus neutralization assay for detection and quantitation of serum-neutralizing antibodies to influenza A virus in swine. Methods in molecular biology (Clifton, NJ). 2014;1161:313-24.